Chen ZX, et al. - Researchers examined patients initially treated with transarterial chemoembolization (TACE) for hepatitis B-related hepatocellular carcinoma, to determine clinical parameters and treatment needs for long-term survival in these patients. They performed a comparison between patients who survived for >3 years and those who died within 3 years. The factors that were found to be related to a 3-year survival were body mass index, antivirus treatment, tumor status, hepatic function, and α-fetoprotein level. Among participants, long-term survival was not negatively influenced by distant metastasis. In patients who received add-on resection and/or ablation following TACE, the single barrier to long-term survival was vascular invasion.